Small Cap Feast
Small Cap Feast – 15/09/21
Dish of the Day:
No joiners today.
No joiners today.
Off the Menu:
No leavers today.
No leavers today.
What’s Cooking in the IPO Kitchen?
Peel Hunt, a UK mid and small-cap specialist investment bank, announces its intention to seek admission of its ordinary shares to trading on AIM. Admission is expected to take place on or around 29 September. In conjunction with a placing of Ordinary Shares the Company will be conducting an intermediaries offer.
Oxford Nanopore Tech—expected intention to float on the LSE (Standard). The company behind a new generation of nanopore-based sensing technology, whose first products enable the real-time, high-performance, scalable analysis of DNA and RNA. Timing and offer TBA.
Fruugo.com which owns and operates a high growth and profitable global cross-border marketplace employing its own proprietary technology and data science, announces its intention to seek admission of its shares to trading on AIM. Due early Oct. Timing and offer TBA.
Optima Health is the UK’s leading provider by size of technology enabled corporate health and wellbeing solutions. To join AIM late Sep. Offer TBA.
Petershill Partners, Expected Intention to Float on the London Stock Exchange. Petershill Partners, a leading investment group providing bespoke capital and strategic solutions to some of the world’s best performing alternative asset management firms. Petershill Partners today comprises minority investments in 19 high-quality Partner-firms, previously held in private funds managed by Goldman Sachs Asset Management (GSAM). The Partner-firms have US$187 bln of aggregated assets under management. The Ordinary Shares would be admitted to the Premium Segment of the Official List of the FCA and to trading on the Main Market of the LSE. The Offer would comprise (i) the issue of new Ordinary Shares, raising Gross Primary Offer Proceeds of approximately US$750m to fund ongoing expenses and acquire further Alternative Asset Manager Stakes and (ii) the sale of existing Ordinary Shares in order to achieve a free float of 25%.Timing TBA
GreenRoc Mining to join AIM. Established in March 2021 as a UK public limited company for the purpose of acquiring all of the Greenlandic mining assets of Alba Mineral Resources plc and progressing the exploration and development of those assets. The assets in question are the Thule Black Sands Ilmenite Project, the Amitsoq Graphite Project, the Melville Bay Iron Project and the Inglefield Multi-Element Project. Greenland will be the main country of operation. Gross funds raised on admission: £5.12m. Anticipated Mkt Cap on Admission: £11.120m. Due mid-September
Responsible Housing REIT to join the Main Market (Premium) in late September raising up to £250m. The Company’s investment objective is to generate a consistent and sustainable income-based return from the provision of Supported Housing accommodation assets and aligned sectors.
Blackfinch Renewable European Income Trust plc, a closed-end investment trust established to invest in a diversified portfolio of mixed renewable energy infrastructure assets, is considering proceeding with an initial public offering and has published a registration document. Raising up to £300m. Due on the Main Market (Premium) in October.
Central Copper Resources, a company focused on delivering a high grade copper project into production and exploration of assets in the Democratic Republic of the Congo (DRC) and in the Republic of Zambia to join AIM. By 2022, CCR intends to be ready to commence the project financing of its Mbamba Kilenda copper project. Offer TBA. Due Late September.
Euro Sun Mining Inc (TSX:ESM) seeking to join the Main Market in Q3 2021. The Company’s main asset, the Rovina Valley Project, which contains the Rovina, Colnic and Ciresata deposits, is one of the largest undeveloped copper-gold projects in Europe, holding approximately 400Mt of confirmed resources containing 7.0m ounces of gold and 1.4 bn lbs of copper.
4d Pharma 75p £135m (DDDD.L)
The pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces new biomarker analyses from two ongoing clinical trials of its lead immuno-oncology single strain Live Biotherapeutic, MRx0518, in both neoadjuvant and refractory solid tumor settings, at the European Society for Medical Oncology (ESMO) Congress, September 16-21, 2021. “At the core of 4D pharma’s platform is the importance of understanding the impact of Live Biotherapeutics on human biology to rationally select and develop candidates, predict and measure response. These new biomarker data provide us with critical guidance on the biological and mechanistic impact of MRx0518 therapy in patients with various solid tumors,” said Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma. “These new findings indicate the potential to predict patients most likely to respond to MRx0518 therapy based on tumor biology.” “Furthermore, the monotherapy data demonstrates that a short course of MRx0518 treatment is able to positively modulate prognostic indicators of immunotherapy response,” he added. “We look forward to utilizing and implementing these important new findings as we work to progress this novel oncology Live Biotherapeutic through development towards approval.”
Crossword Cybersecurity* 33.5p £25.1m (CCS.L)
The technology commercialisation company focused on cyber security and risk management announced the appointment of Alison Dyer, Chief Information Security Officer at URENCO and former Director at GlaxoSmithKline (GSK), who joins the Crossword Advisory Board as Chair. She takes over from Dr Robert Coles who has moved to Crossword’s main Board of Directors. The Advisory Board, made up of senior figures from academia, the corporate world, defence and government, provides a range of unique perspectives on cyber security that benefit Crossword clients and inform Crossword’s product development strategy. Alison Dyer joined URENCO, a global supplier of enrichment services and fuel cycle products, in 2018 and is responsible for all aspects of their information and cyber security, covering both information and operational technology. Prior to this Alison was Director of GlaxoSmithKline’s (GSK) global cyber security programme, where she led multiple strategic delivery workstreams including security technology, governance, culture, third party management and operational technology security. Alison holds a BEng in Mechanical Engineering from Imperial College, London and an MSc in Information Security from Royal Holloway University.
Futura Medical 39.6p £113.7m (FUM.L)
The pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that the first patient visit has occurred in the confirmatory clinical study, FM71, for MED3000 that will be supporting the US regulatory submission for the product. MED3000 is a breakthrough, fast acting topical gel formulation for the treatment of erectile dysfunction (ED) and is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction. The start of FM71 is in line with planning and both the FM71 and non-clinical Human Factors studies are now progressing in parallel targeting patient completion by the end of Q2 2022 in order for submission of MED3000 for US regulatory approval as a DeNovo medical device for ED treatment, with OTC classification by end Q3 2022. US marketing authorisation therefore remains on track for approval of MED3000 in Q1 2023.
Hornby 43.5p £73.4m (HRN.L)
AGM Trading Update from the international models and collectibles group. “For the period from the 1st April to the 31st August 2021, sales and margins have been slightly lower than the previous year but in line with internal budgets. Trading patterns have begun to return to those experienced in pre-covid times. On 30 July 2021, the Group completed the acquisition of the remaining 51% of LCD Enterprises Limited for a cash consideration of £1.3m. As is usually the case in our industry; the outcome for the full year is subject to the sales rate over the key Christmas trading period. Our outstanding order book is very strong and substantially higher than a year ago, however timing is everything when it comes to Christmas and we are mindful of the potential supply disruption at the ports continuing.”
Intuitive Investments 18.25p £7.4m (IIG.L)
Investment of £125k to acquire 25,000 new A preferred shares in Momentum Bioscience Limited as part of a £3.89m fundraising round. The Investment provides IIG with a 2.4% interest in Momentum’s share capital as enlarged by the Fundraising. Momentum is developing a revolutionary rapid diagnostic test for patients suspected of sepsis, an infection of the blood stream resulting in symptoms including a drop in a blood pressure, increase in heart rate and fever. Last year, the World Health Organisation (WHO) reported that there were 49m deaths from sepsis globally and 11m avoidable deaths. The current standard of care typically takes 1-5 days to detect viable bacteria or fungi (organisms) in blood, relying on downstream workflows to provide an identification of the organism thereafter. Momentum’s SepsiSTAT® system enables reporting of the presence or absence and ‘pan gram identification’ of viable organisms in just two hours, helping direct the right antimicrobials. The system also provides a pure concentrate of growing organisms for further analysis.
Lexington Gold 4.2p £11m (LEX.L)
The gold exploration and development company with projects in North and South Carolina, USA, has received notification from FTE Drilling with regards to a revised schedule for the commencement of the 5,000m RC drilling programme. In order to facilitate routine drill rig maintenance, the allocated drill rig and crew is now scheduled to arrive on site during the week commencing 4 October 2021 rather than the previously announced date of the week commencing 20 September 2021.
Oracle Power 0.34p £7.8m (ORCP.L)
The international natural resources project developer announced that, as anticipated following the approval of the Programme of Work, the drill programme is underway at the Northern Zone Gold Project, located 25km east of Kalgoorlie in Western Australia. The first phase is to complete 7 Reverse Circulation (RC) drillholes up to 260 metres deep, for a total of ~1,500 metres specifically targeting gold mineralisation within a series of stacked porphyry intrusions.
Physiomics* 6.3p £6m (PYC.L)
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions will publish its results for the full year ending 30 June 2021 on Thursday, 30 September. Dr Jim Millen, CEO of Physiomics, will provide a live presentation relating to the Company’s full year results via the Investor Meet Company platform on 30 September at 2pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your the ‘Investor Meet Company’ dashboard up until 9:00 a.m. the day before the meeting or at any time during the live presentation. Investors who already follow Physiomics plc on the Investor Meet Company platform will automatically be invited. Potential investors can sign up to ‘Investor Meet Company’ for free and register to join the presentation via https://www.investormeetcompany.com/physiomics-plc/register-investor.
Sabien Technology 25.25p £3.7m (SNT.L)
The Company focused on building a portfolio of solutions in the heating, cooling, and transportation sectors, announces today an agreement with City Oil Field Incorporated of South Korea. The agreement provides that Sabien acts as an exclusive sales agent for COF in the UK, with non-exclusive rights in other territories, for an initial period of 1 year. A longer-term relationship is anticipated, and future sales targets have been agreed in outline. COF’s proprietary technology and techniques, collectively a Resource Gathering Operation (RGO), focus on the production of light and ultra-pure fuel products from low temperature processing of end-of-life plastics. This process involves the catalytic degradation of waste plastics and vinyl materials via a wave energy application utilising specifically designed ceramic ball catalysts. This enables the required degradation to occur at low temperatures (200°C to 270°C), producing a heavy oil. A further refinement process, which also makes use of the ceramic ball technology, leads to production of a highly refined, ultra-pure fuel product (i.e. a fuel from waste).
Tatton Asset Management 546p £316m (TAM.L)
The investment management and IFA support services group announced the acquisition of £650m Verbatim funds for a cash consideration of up to £5.8m and a long-term strategic distribution partnership with Fintel plc (AIM: FNTL), a leading provider of fintech and support services to the UK retail financial services sector. The transaction supports the Group’s strategy to grow assets under management (AUM) through both acquisition and through strategic partnerships that extend its distribution channels facilitating further organic growth; The acquisition of the Verbatim multi-asset and multi-index funds adds c.£650m to Tatton Investment Management’s AUM, complementing and extending our existing fund range; The five-year strategic distribution partnership with Fintel plc provides access to over 3,800 new financial intermediary firms and its 6,000 Defaqto users, significantly enhancing our reach and distribution to further contribute to the organic growth of our AUM; and the technology provides insights and analysis, enabling targeted product design and distribution further benefiting the Group through access to 2,500 market-leading fintech licences to distribute to Tatton and Paradigm firms and users. The transaction, which includes both the acquisition of the funds and a five-year strategic distribution partnership agreement, is expected to be earnings enhancing in the financial year ending 31 March 2022 and beyond; over the remainder of FY22, the partnership, including the Verbatim funds, is expected to generate adjusted operating profit of c.£0.6m, with adjusted operating profit of c.£1.5m expected in FY23, the first full financial year.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.